Abstract
We report in-concert dynamics of 18 key immune parameters, related to clinical, genetic and virological factors, in patients hospitalized with influenza across different severity levels. Influenza disease was associated with correlated increases in IL6/IL-8/MIP-1α/β cytokines and lower antibody responses. Robust activation of circulating T follicular helper cells (cTfhs) correlated with peak antibody-secreting cells (ASC) and influenza heamaglutinin-specific memory B-cell numbers, which phenotypically differed from vaccination-induced B-cell responses. Influenza-specific CD8+/CD4+ T-cells increased early in disease and remained activated during patient recovery. Here, we describe the broadest to-date immune cellular networks underlying recovery from influenza infection, highly relevant to other infectious diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Australian National Health and Medical Research Council (NHMRC) NHMRC Program Grant (1071916) to KK, SJT, NLG, AK, DCJ, LEB, WC supported this work. MK and SN were recipients of Melbourne International Research Scholarship and Melbourne International Fee Remission Scholarship. CES has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement 792532. EBC is a NHMRC Peter Doherty Fellow. MA and LH are recipients of Melbourne International Research Scholarship and Melbourne International Fee Remission Scholarship. SS was a recipient Victoria India Doctoral Scholarship and Melbourne International Fee Remission Scholarship, University of Melbourne. The Melbourne WHO Collaborating Centre for Reference Research on Influenza is supported by the Australian Government Department of Health. SG is a NHMRC SRF-Level A Fellow. JR is supported by an ARC Laureate fellowship. NLG is supported by a NHMRC Ideas grant, ARC Discovery Project and ARC Future Fellowship. PGT is supported by the St. Jude Center of Excellence for Influenza Research and Surveillance (NIAID Contract HHSN27220140006C), R01 AI 107625, R01AI136514 and ALSAC. ACC is a NHMRC Career Development (level 2) Fellow. KK was supported by a NHMRC Senior Research Fellowship Level B (1102792), NHMRC Investigator Grant (1173871) and the University of Melbourne Dame Kate Campbell Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human experimental work was conducted according to the Declaration of Helsinki Principles and according to the Australian National Health and Medical Research Council Code of Practice. All participants provided written informed consent prior to the study. The study was approved by the Alfred Hospital (ID #280/14) and University of Melbourne (ID #1442952.1 and #1443389.4) Human Research Ethics Committees.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
KLL is currently at Seqirus, Parkville 3052, Victoria, Australia.
Data Availability
All data are available upon request
